Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 16, Art. 81 (pp. 916-933)    |    2015       

»

New ways to improve the mobilization of hematopoietic stem cells: literature review

1N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia
2Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russia
3North-Western state medical University named I. I. Mechnikov, St.Petersburg, Russia

Brief summary

The study of hematopoietic stem cells mobilization and most recent approaches to usage of new mobilizing agent plerixafor are reveals in the article. The research of plerixafor interacting with various growth factors including pegylated filgrastim is considered to be the most promising direction. This method is believed to help patients with low mobilizing activity where all other means have failed to improve it. The possibility of obtaining a sufficient number of hematopoietic material using plerixafor allows us to perform a course of high-dose chemotherapy with stem cell transplantation in time and therefore achieve high results in patients with a poor prognosis.


Key words

hematopoietic stem cells, hematopoietic stem cells mobilization, high-dose chemotherapy, pleriхafor, pegfilgrastim

Reference list

1. Volkova M.A. Klinicheskaya onkogematologiya // M.: Medicina. - 2007. - 1120 s.


2. Pokrovskaya O.S. Mehanizm deistviya i klinicheskaya effektivnost antagonista hemokinovogo receptora CXCR4 pleriksafora pri mobilizacii gemopoeticheskih stvolovih kletok // Klinicheskaya onkogematologiya. - 2012. - N 4. - S. 371-379.


3. Attal M., Harousseau J.L., Stoppa A.M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma // N. Engl. J. Med. - 1996. - Vol. 335. - P. 9197.


4. Auner H.W., Mazzarella L., Cook L. et al. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma // Bone Marrow Transplant. - 2011. - Vol. 46. - N 3. - R. 364-367.


5. Avecilla S.T., Hattori K., Heissig B. et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis // Nat. Med. - 2004. - Vol. 10. - N 1. - P. 64-71.


6. Bakany S.M, Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients // J. Bone Marrow Transplant. - 2012. - V. 47. - P. 1154-1163.


7. Calandra G., McCarty J., McGuirk J. et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin?s lymphoma, Hodgkin?s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data // Bone Marrow Transplant. - 2008. - Vol. 41. - N 4. - R. 331-338.


8. Calvi L.M., Adams G.B. Osteoblastic cells regulate the haematopoietic stem cell niche // Nature. - 2003. - Vol. 425. - P. 841-846


9. Costa L.J., Kramer C., Hogan K.R. et al. Pegfilgrastim versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis // Transfusion. - 2012. - Vol. 52. - N 11. - P. 2375-2381.


10. Crowther D., Wagstaff J., Deakin D. et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin?s disease // J. Clin. Oncol. - 1984. - Vol. 2. - P. 892-898.


11. Di Persio J.F., Micallef I.N., Stiff P.J. et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma // J. Clin. Oncol. - 2009. - Vol. 27. - N. 28. - P. 4767-4773.


12. Di Persio J.F., Stadtmauer E.A, Nademanee A. et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma // Blood. - 2009. - Vol. 113. - N 23. - P. 5720-5726.


13. Dreger P., Kloss M., Petersen B. et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and en- graftment of peripheral blood progenitor cell but not of bone marrow grafts // Blood. - 1995. - Vol. 86. - N 10. - P. 3970-3978.


14. Greenbaum A.M., Link D.C. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization // Leukemia. - 2011. - Vol. 25. - N 2. - P. 211-217.


15. Hoppe R., Cox R., Rosenberg S., Kaplan H. Prognostic factors in pathologic stage III Hodgkin?s disease // Cancer Treat. Rep. - 1982. - Vol. 66. - P. 743-748.


16. Jantunen E., Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies // Eur. J. Haematol. - 2010. - Vol. 85. - P. 463-471.


17. Kiel M.J., Yilmaz O.H., Iwashita T. et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells // Cell. - 2005. - Vol. 121. - P. 1109-1121.


18. Kiel M.J., Morrison S.J. Uncertainty in the niches that maintain haematopoietic stem cells // Nat. Rev. Immunol. - 2008. - Vol. 8. - N 4. - P. 290-301.


19. Kim M.G., Han N., Lee E.K., Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis // Bone Marrow Transplant. - 2015. - Vol. 10. - P.1038.


20. Korbling M., Przepiorka D., Gajewski J. et al. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? // Blood. - 1995. - Vol. 86. - P. 1235-1238.


21. Kotasek D., Shepherd K. M., Sage R. E. et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma, and solid tumors // Bone Marrow Transplant. - 1992. - Vol. 9. - P. 11-17.


22. Krause D.S., Fackler M.J., Civin C.I., May W.S. CD34: structure, biology, and clinical utility // Blood. - 1996. - Vol. 87. - N 1. - P. 1-13.


23. Linch D.S., Winfield D.W., Goldstone A.H. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin?s disease, results of BNLI randomized trial // Lancet - 1993 - Vol. 341 - P.1051-1054.


24. Martino M., Laszlo D., Lanza F. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization // Expert Opin. Biol. Ther. - 2014. - Vol. 14. - N 6. - P. 757-772.


25. Maximow, A.A. Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere // A.A. Maximov. - B.: Folia Haematologica, 1909. - P. 125-134.


26. Moskowitz C.H., Glassman J.R., Wuest D. et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma // Clin. Cancer Res. - 1998. - Vol. 4. - P. 311-316.


27. Nademanee A.P., DiPersio J.F., Maziarz R.T. et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial // Biol. Blood Marrow Transplant. - 2012. - V. 18. - N 10. - P. 1564-1572.


28. Pelus L.M. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand // Curr. Opin. Hematol. - 2008. - Vol. 15. - P. 285-292.


29. Pfreundschuh M.G., Schoppe W.D., Fuchs R. et al. CEVD in Hodgkin?s lymphoma, refractory to COPP and ABVD, a multicenter trial of German Hodgkin Study Group // Cancer Treated. Report. - 1987. - Vol. 72. - P. 1203-1207.


30. Philip T., Gauglielmi C., Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin?s Lymphoma // New Engl. J. Med. - 1995. - Vol. 333. - P. 1540-1545.


31. Richard A. Rettig, Peter D. Jacobson. False Hope: Bone Marrow Transplantation for Breast Cancer // J. Health Polit. Policy Law. - 2007. - Vol. 32. - N 5. - P. 785-818.


32. Richman C.M., Weiner R.S., Yankee R.A. Increase in circulating stem cells following chemotherapy in man // Blood. - 1976. - Vol. 17. - P. 1031-1039.


33. Rowlings P.A., Bayly J.L., Rawling C.M. et al. A comparison of peripheral blood stem cell mobilization after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer // Aust. N. Z. J. Med. - 1992. - Vol. 22. - P. 660-664.


34. Santoro A., Viviani S.S., Valagussa P. et al. CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin?s disease // Semin. Oncol. - 1986. - Vol. 13. - P. 23-28.


35. Schmitz N. High dose BEAM chemotherapy in patients with relapsed and refractory Hodgkin?s disease // Oncol. Rev. - 1998. - Vol. 13 - P. 13.


36. Shiozawa Y., Taichman R.S. Getting blood from bone: an emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche // Exp. Hematol. - 2012. - Vol. 40. - N 9. - P. 685-694.


37. Siena S., Schiavo R., Pedrazzoli P. et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy // J. Clin. Oncol. - 2000. - Vol. 18. - P. 1360-1377.


38. To L.B., Shepherd K.M., Haylock D.N. et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood // Exp. Hematol. - 1990. - Vol. 18. - P. 442-447.


39. Wilson A., Trumpp A. Bone-marrow haematopoietic-stem-cell niches // Nat. Rev. Immunol. - 2006. - Vol. 6. - N 2. - P. 93-106.


40. Wuchter P., Ran D., Bruckner T., et al. Poor Mobilization of Hematopoietic Stem Cells - Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation // Biol. Blood Marrow Transplant. - 2010. - Vol. 16. - P. 490-499.